Novo Nordisk will not increase its proposal to acquire Metsera, Inc.

Core Viewpoint - Novo Nordisk has confirmed it will not increase its offer to acquire Metsera, despite previous proposals being declared superior by Metsera's board of directors [1][4]. Group 1: Acquisition Proposals - On October 30, 2025, Novo Nordisk submitted an unsolicited proposal to acquire Metsera, which was declared superior by Metsera's board [1]. - An updated proposal was submitted on November 4, 2025, offering $62.20 per share in cash, totaling approximately $7.2 billion in equity value and $6.7 billion in enterprise value, along with contingent value rights (CVRs) of up to $24.00 per share based on certain milestones [2]. - A revised proposal was made on November 6, 2025, increasing the offer to $65.60 per share in cash, amounting to about $7.6 billion in equity value and $7.1 billion in enterprise value, with CVRs of up to $20.65 per share based on specific milestones [3]. Group 2: Strategic Focus - Novo Nordisk emphasizes its commitment to financial discipline and shareholder value, which influenced the decision not to increase the acquisition offer [4]. - The company is focused on advancing a diverse pipeline of treatment options for obesity and continues to invest in next-generation assets to address the needs of individuals with diabetes and obesity [5]. - Novo Nordisk is committed to assessing business development and acquisition opportunities that align with its strategic objectives and capital allocation criteria [5]. Group 3: Company Overview - Novo Nordisk is a leading global healthcare company founded in 1923, headquartered in Denmark, and employs approximately 78,500 people across 80 countries [6]. - The company markets its products in around 170 countries and is listed on Nasdaq Copenhagen and the New York Stock Exchange [6].